The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes
Abstract
OBJECTIVE—This open-label, active-controlled study investigated the cardiac safety and antihyperglycemic effect of rosiglitazone (RSG) in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS—Of the 203 patients randomly assigned to RSG (4 mg b.i.d.) or glyburide (GLB) (titrated to achieve optimal glycemic control for the first 8 weeks only to limit the risk of hypoglycemia; mean 10.5 mg/day), 118 had an echocardiogram performed at week 52. Left ventricular (LV) mass index, ejection fraction, and left ventricular end-diastolic volume were assessed by M-mode echocardiography at baseline and weeks 12, 28, and 52; 24-h ambulatory blood pressure was assessed at baseline and at weeks 28 and 52. Glycemic control was assessed by measuring fasting plasma glucose (FPG) and HbA1c. RESULTS—Neither treatment produced an increase in LV mass index that exceeded 1 SD. Ejection fraction did not change in either group. Both groups had clinically insignificant increases in LV end-diastolic volume. RSG, but not GLB, caused a statistically significant reduction in ambulatory diastolic blood pressure. Both treatments reduced HbA1c and FPG. CONCLUSIONS—A total of 52 weeks of therapy with RSG (4 mg b.i.d.) did not adversely affect cardiac structure or function in patients with type 2 diabetes and produced significant and sustained reductions in hyperglycemia. Decreases in ambulatory diastolic blood pressure with RSG were superior to those with GLB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., & Reichek, N. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90771-x · Cited by 6,229
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.280 · Cited by 518
Self-citation&NA;, &. (1993) · Journal of Hypertension · doi:10.1097/00004872-199303000-00012 · Cited by 488
Thiazolidinediones: a new class of antidiabetic drugs
Day, C. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00023.x · Cited by 436
Groop, L. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.737 · Cited by 408 · cited 1×
“The overall frequency of AEs was similar in the two treatment groups and characteristic of previous observations (2,3,25).”
ResultCardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM
Ghazzi, M. N., Perez, J. E., Antonucci, T. K., Driscoll, J. H., Huang, S. M., Faja, B. W., The Troglitazone Study Group, & Whitcomb, R. W. (1997) · Diabetes · doi:10.2337/diab.46.3.433 · Cited by 366
Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat
Haliakon, S., Doaré, L., Foufelle, F., Kergoat, M., Guerre-Millo, M., Berthault, M.-F., Dugail, I., Morin, J., Auwerx, J., & Ferré, P. (1997) · Diabetes · doi:10.2337/diab.46.9.1393 · Cited by 306
Phillips, L. S., Grunberger, G., Miller, E., Patwardhan, R., Rappaport, E. B., Salzman, A., & the Rosiglitazone Clinical Trials Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.2.308 · Cited by 302
Self-citationEnhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
OGIHARA, T., RAKUGI, H., IKEGAMI, H., MIKAMI, H., & MASUO, K. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)96214-5 · Cited by 274
Sample size requirements for evaluating a conservative therapy.
Makuch, R., & Simon, R. M. (1978) · PubMed · Cited by 228
Cited by
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 829
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Metadata
- Authors
- St. John Sutton, M., Rendell, M., Dandona, P., Dole, J. F., Murphy, K., Patwardhan, R., Patel, J., Freed, M., & For the Rosiglitazone Clinical Trials Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2002-11-01
- Volume
- 25
- Issue
- 11
- Pages
- 2058-2064
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2102319947
- Cited by
- 254
- References
- 21
- FWCI
- 13.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/diacare.25.11.2058
- The paper
- St. John Sutton, M., Rendell, M., Dandona, P., Dole, J. F., Murphy, K., Patwardhan, R., Patel, J., Freed, M., & For the Rosiglitazone Clinical Trials Study Group. (2002). A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/diacare.25.11.2058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.